ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) was the target of a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 5,600 shares, a drop of 53.7% from the May 15th total of 12,100 shares. Based on an average daily trading volume, of 28,700 shares, the short-interest ratio is currently 0.2 days.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its holdings in ProShares Ultra Nasdaq Biotechnology by 523.9% in the third quarter. Tower Research Capital LLC TRC now owns 6,457 shares of the exchange traded fund’s stock valued at $310,000 after buying an additional 5,422 shares in the last quarter. Toth Financial Advisory Corp grew its position in shares of ProShares Ultra Nasdaq Biotechnology by 17.3% in the fourth quarter. Toth Financial Advisory Corp now owns 11,241 shares of the exchange traded fund’s stock valued at $641,000 after purchasing an additional 1,655 shares during the period. Palumbo Wealth Management LLC acquired a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the fourth quarter valued at about $228,000. Clarity Capital Partners LLC acquired a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the fourth quarter valued at about $201,000. Finally, IMC Chicago LLC acquired a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the fourth quarter valued at about $2,435,000.
ProShares Ultra Nasdaq Biotechnology Trading Down 1.5 %
Shares of ProShares Ultra Nasdaq Biotechnology stock traded down $0.89 during trading on Friday, hitting $58.65. 83,994 shares of the company’s stock were exchanged, compared to its average volume of 33,238. The business has a 50-day simple moving average of $54.73 and a 200-day simple moving average of $55.58. ProShares Ultra Nasdaq Biotechnology has a 52-week low of $40.10 and a 52-week high of $62.45.
ProShares Ultra Nasdaq Biotechnology Dividend Announcement
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Read More
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 6/10 – 6/14
- Insider Trades May Not Tell You What You Think
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- What is the S&P/TSX Index?
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.